Charles Burger, MD
Pulmonary Disease · Jacksonville, FLNPI 1790772671
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $107,976 of the $124,190 with a category attached, or 86.9%. 11 manufacturers reported payments, led by Insmed, Inc. at 31.0% of the total. Reporting peaked in 2024 at $55,767 and has fallen 57.1% since, to $23,922 in 2025. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 179 payments — averaging $693.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$39K
- Actelion Pharmaceuticals US, Inc.$33K
- Merck$32K
- United Therapeutics Corporation$9K
- Janssen Scientific Affairs, LLC$9K
- Bayer$2K
- plus $759 from 5 others
Across 259 payments — averaging $21,043 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$4.6M
- United Therapeutics Corporation$428K
- Insmed, Inc.$134K
- Sumitomo Pharma America, Inc.$106K
- Actelion Pharmaceuticals, Ltd$87K
- Janssen Research & Development, LLC$56K
- plus $14K from 1 others
What the payments were for
- Consulting fees$107,97687%
- Travel & lodging$7,4266%
- Food & beverage$8,7327%
- Education$560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 6 | $38,535 |
| Actelion Pharmaceuticals US, Inc. | 59 | $33,007 |
| Merck | 43 | $32,133 |
| United Therapeutics Corporation | 52 | $9,131 |
| Janssen Scientific Affairs, LLC | 6 | $8,524 |
| Bayer | 2 | $2,100 |
| Actelion Pharmaceuticals, Ltd | 6 | $479 |
| Chiesi USA, Inc. | 1 | $110 |
| Johnson & Johnson | 1 | $77 |
| Sandoz | 2 | $74 |
| Philips North America LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$124,190 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 190 | $2,379,756 |
| AdempasRiociguat | 125 | $1,699,216 |
| UptraviSelexipag | 43 | $969,576 |
| Ambrisentan | 201 | $732,029 |
| Tyvaso DpiTreprostinil | 12 | $516,179 |
| LetairisAmbrisentan | 27 | $310,721 |
| Orenitram ErTreprostinil Diolamine | 12 | $308,860 |
| TracleerBosentan | 12 | $149,659 |
| Tadalafil | 126 | $142,726 |
| AdcircaTadalafil | 12 | $46,782 |
| Sildenafil Citrate | 160 | $36,251 |
| Bosentan | 11 | $13,690 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $10,953 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $8,663 |
| Bumetanide | 28 | $1,987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Tracleer, Bosentan | $33,007 | $3,512,680256 claims |
| BayerAdempas | $2,100 | $1,699,216125 claims |
| United Therapeutics CorporationAdcirca | $9,131 | $46,78212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Jacksonville
- Jennifer FultonJacksonville$665K
- Jose Soto SotoJacksonville$504K
- Jorge MalleaJacksonville$457K
- Abubakr BajwaJacksonville$414K
- Bryan HustaJacksonville$283K
- Sebastian Fernandez-BussyJacksonville$257K
- Peter NassarJacksonville$141K
- Daniel WyzanJacksonville$100K
- David Abia TrujilloJacksonville$68K
- Franck RahaghiWeston$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.